lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-03. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
== Other rhEGFs == Several other products containing recombinant human EGF have been marketed. The potencies of these products can differ by the expression system used, despite all intending to match the structure of human EGF. Instead of measuring by mass, the international unit system from the World Health Organization provides a way to describe the potency-adjusted amount of rhEGF. However, the WHO does not prescribe a specific way of measuring the potency. rhEGF bioassay remains a field in active development.
==== Codon models ==== Codon models describe the evolution of protein-coding nucleic acid sequences. The simplest codon model, MG, estimates one parameter: nonsynonymous/synonymous mutation ratio. The more complex GY also estimates transition/transversion rate ratios. Both of these are mechanistic models. They can be expanded by the addition of rate parameters. Empirical codon models directly describe the odds of one non-stop codon (61 in the standard code) being replaced by another, making them similar to amino acid exchangability matrices. By their construction, they are tied to the genetic code found in the data used to construct them. They can also be combined with a mechanistic model by multiplying the two estimated rates, adding back the ability to adapt to the data being processed.
From October 1940 to May 1941, during the Franco-Thai War, the Vichy French in Indochina defended their territories in a border conflict in which the forces of Thailand invaded while the Japanese sat on the sidelines. Thai military successes were limited to the Cambodia–Thailand border area, and in January 1941 Vichy France's modern naval forces soundly defeated the inferior Thai naval forces in the Battle of Ko Chang. The war ended in May, with the French agreeing to minor territorial revisions which restored formerly Thai areas to Thailand. In 1941, Hồ Chí Minh formed the Viet Minh (League for the Independence of Vietnam). He founded the Việt Minh as an umbrella organization, seeking to appeal to a base beyond his own communist beliefs by emphasizing national liberation instead of class struggle. In 1941, Hồ and the Indochinese Communist Party founded a communist-led united front to oppose the Japanese. In March 1945, with the World War all but lost, Japan launched a coup d'état to oust the Vichy French, and formally installed Emperor Bảo Đại as head of a nominally independent Vietnam. The Japanese arrested and imprisoned most of the French officials and military remaining in the country. In Hanoi on 15–20 April 1945, the Tonkin Revolutionary Military Conference of the Việt Minh issued a resolution (reprinted 25 August 1970 in the Nhân Dân journal) calling for a general uprising, resistance and guerrilla warfare against the Japanese.
The bactericidal effects of β-lactam antibiotics are achieved through inhibition of the bacterial cell wall synthesis. The cell wall of both gram-positive and gram-negative bacteria is a tight covalently bound and cross-linked peptidoglycan network and essential for bacterial growth, cell division and cellular structure. Therefore, bacteria need enzymes that can cleave the cell wall during bacterial growth and cell division. The cell wall of bacteria is built up in two steps from the outside of the cell. In the first step, molecules of disaccharide units linked with peptides on their ends are transported from the cytoplasm of the bacteria and joined on the outside of the wall by a transglycolase. In the second step, a transpeptidase links together long polysaccharide chains which are linked together through peptide bonds. The amino acid sequence of D-alanyl-D-alanine is recognized by the transpeptidase at the end of the peptide chain. The enzyme cleaves off the alanine on the terminal end and joins the remainder to a peptide chain from an adjacent polysaccharide. This transpeptidation reaction is inhibited by β-lactam antibiotics like cephalosporins. Because of this inhibition the antibiotics are most effective when the bacteria are in the logarithmic phase of growth, where then they are synthesizing the cell wall. If the bacteria are in the stationary phase of growth, then there is no wall synthesizing in progress, and the antibiotics have much lower effect.
Sources: en.wikipedia.org
Over 2000 compounds were tested randomly in a guinea pig ileum test and succinyl-L-proline was found to have the properties of a specific ACE inhibitor. It showed inhibitory effect of angiotensin I and bradykinin without having any effects on angiotensin II. Then researchers started to search for a model that would explain inhibition on the basis of specific drug interactions of compounds with the active site of ACE. Previous studies with substrates and inhibitors of ACE suggested that it was a zinc-containing metalloprotein and a carboxypeptidase similar to pancreatic carboxypeptidase A. However ACE releases dipeptides rather than single amino acids from the C-terminus of the peptide substrates. And it was assumed that both their mechanism of action and their active site might be similar. A positively charged Arg145 at the active site was thought to bind with the negatively charged C-terminal carboxyl group of the peptide substrate. It was also proposed that ACE binds by hydrogen bonding to the terminal, non scissile, peptide bond of the substrate. But since ACE is a dipeptide carboxypeptidase, unlike carboxypeptidase A, the distance between the cationic carboxyl-binding site and the zinc atom should be greater, by approximately the length of one amino acid residue. Proline was chosen as the amino acid moiety because of its presence as the carboxy terminal amino acid residue in teprotide and other ACE inhibitors found in snake venoms. Eleven other amino acids were tested but none of them were more inhibitory.
=== Candidacy for mayorship of Porto Alegre in 2016 === In 2016, Melo was the candidate for the mayorship of PMDB, with state deputy Juliana Brizola, of the PDT, as the vice-mayoral candidate on the ticket. In the first round, they received 185,655 votes (25.93%). They came in second place behind Nelson Marchezan Júnior, and both qualified for the second round. Melo received a diverse array of support, including from the PCdoB, the PMN, and from the PV's candidate, Marcelo Chiodo, even as his party supported Marchezan Júnior. He also positioned himself as more to the left, announcing his support for the fight against PEC 241, which established a ceiling for public spending for twenty years in Brazil, also going against the national position of his party. Along with this, he affirmed his position against proposed laws inspired by Escola sem Partido, a conservative movement. Melo declared that he had an "identity of struggles" with the left, since he came from the "old MDB", as the party was the main political force against the military dictatorship. As a candidate, he had shown opposition against the privatization of public companies, such as DMAE, Procempa and Carris, and defended participatory budgeting. After a tense campaign with constant trading of accusations between him and Marchezan Júnior, Melo was defeated in the second round, receiving 262,601 votos (39.50%). After the election, on analyzing his defeat in an interview, Melo criticized the possibility that the MDB would become a part of his adversary's administration.
=== Comparison with other expression systems === In standard molecular biology research, the bacterium Escherichia coli is the most frequently used organism for expression system, to produce heterologous proteins, due to its features of fast growth rate, high protein production rate, as well as undemanding growth conditions. Protein production in E. coli is usually faster than that in Komagataella, with reasons: Competent E. coli cells can be stored frozen, and thawed before use, whereas Komagataella cells have to be produced immediately before use. Expression yields in Komagataella vary between different clones, so that a large number of clones has to be screened for protein production, to find the best producer. The biggest advantage of Komagataella over E. coli is that Komagataella is capable of forming disulfide bonds and glycosylations in proteins, but E. coli cannot. E. coli might produce a misfolded protein when disulfides are included in final product, leading to inactive or insoluble forms of proteins. The well-studied Saccharomyces cerevisiae is also used as an expression system with similar advantages over E. coli as Komagataella. However Komagataella has two main advantages over S. cerevisiae in laboratory and industrial settings:
== Production == In November 2024, Amazon MGM Studios was developing an action thriller film titled The Runner with Kevin Macdonald directing, Mark Gibson writing the script, and Gal Gadot starring. Principal photography began on 22 April 2025, in London and wrapped filming around early July 2025. London locations lensed include: Regent's Canal and St Pancras Way, in the London Borough of Camden; Kentish Town; Canary Wharf; Covent Garden; and Hampstead Heath. Some filming was on unclosed live streets, with real crowds and hidden cameras. The setting of Maia's route begins around Hampstead Heath, to Kentish Town, then along Regent's Canal, then down St Pancras Way, then toward King's Cross, London, and London King's Cross railway station. Later, in The City of London, sites include: Watling Street, Coleman Street, and King's Arms Yard. Later, in Canary Wharf and around the Thames river: Millennium Bridge, Waterloo Bridge and HMS Belfast. Through April and May 2025, eight pro-Palestinian protesters in total were arrested for disrupting the Central London set of the film. The film's production schedule, however, was not affected. The Metropolitan Police stated in a news release that the demonstrations were “solely because an actress involved in the production is Israeli." Gadot, who previously served in the IDF for two years, has been described as "vocal in her support of Israel".
Northern Command (Headquarters at Rawalpindi) Central Command (Headquarters at Agra) Southern Command (Headquarters at Poona) Eastern Command (Headquarters at Calcutta) After Independence of Pakistan in 1947, the armed forces reconstitution committee divided the former British Indian Armed Forces which resulted with Pakistan receiving most of Northern Command as part of its share. Between 1958 and 1960, the Military Engineering Services saw notable restructuring with its sub-branches being established after approval by the Ministry of Defense.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.